Barclays PLC Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Barclays PLC increased its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 87.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 324,472 shares of the company’s stock after buying an additional 151,685 shares during the quarter. Barclays PLC owned about 0.22% of Xeris Biopharma worth $925,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in XERS. Wealth Enhancement Advisory Services LLC purchased a new stake in Xeris Biopharma during the 3rd quarter valued at about $35,000. Quantbot Technologies LP acquired a new stake in shares of Xeris Biopharma during the third quarter worth about $44,000. Asset Management Group Inc. boosted its position in Xeris Biopharma by 130.7% in the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after buying an additional 15,000 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Xeris Biopharma in the 2nd quarter worth approximately $75,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Xeris Biopharma by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock worth $82,000 after buying an additional 11,239 shares during the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on XERS shares. HC Wainwright upped their price objective on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a report on Monday, November 11th. Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research report on Monday, November 11th.

Xeris Biopharma Trading Down 2.4 %

Shares of NASDAQ:XERS opened at $3.20 on Wednesday. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.69 and a 12-month high of $3.87. The business has a 50 day moving average of $3.35 and a two-hundred day moving average of $2.92. The company has a market capitalization of $477.06 million, a PE ratio of -7.11 and a beta of 2.62.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.